NETRIS Pharma

Focus: NETRIS Pharma is a French pharmaceutical company headquartered in Lyon specializing in drugs that block ligand-dependence receptor interactions, a novel mechanism targeting specific disease pathways.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About NETRIS Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow NETRIS Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NP137

Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT05546879Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

Phase 1

Help build intelligence for NETRIS Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to proprietary dependence receptor blocking technology, a differentiated mechanism with limited competitor overlap
Opportunity to build from early stage in a focused therapeutic area with potential for significant IP moat
French biotech ecosystem location with access to EU funding and regulatory pathways

Watch Out For

No active clinical trials reported suggests early preclinical stage with extended timeline to clinical validation
Zero active job openings indicates minimal near-term hiring and potential resource constraints

Generated by Claude from NETRIS Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NP137

Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT06203821Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Phase 1

NP137

Pancreatic Ductal Adenocarcinoma

Phase 1

Clinical Trials (1)

NCT05546853Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Phase 1

NP137 DL and RP2D

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT02977195First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors

Phase 1

NP137

Endometrial Carcinoma

Phase 1/2

NP137

Acute Myeloid Leukemia Refractory

Phase 1/2

Clinical Trials (1)

NCT06150040Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

Phase 1/2

NP137

Advanced Solid Tumors

Phase 2

Clinical Trials (1)

NCT05605496NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

6 pipeline

Marketed

Pipeline